Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03912103
Other study ID # VD-2019-09
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 19, 2019
Est. completion date March 5, 2021

Study information

Verified date March 2019
Source Region Hovedstadens Apotek
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Inappropriate medication prescribing is highly prevalent among comorbid medical patients and leading to adverse drug events (ADE), re-admissions, quality of life and mortality. Thus, the aim of this study is primary to investigate the feasibility of a interdisciplinary intervention focused on deprescribing and medication optimization in the Integrated Outpatient Department at Copenhagen University Hospital, Amager, Denmark. Participants in the intervention group receives a medication review by a clinical pharmacist and physician with a follow up after 7 and 30 days. The control group receives standard care.


Description:

The FMA-CPH trial is designed as a single-blinded randomized controlled pilot trial starting at the first consultation and end 30 days after. Patients that meet all inclusion criteria and none of the exclusion criteria are invited to participate. After signing a written informed consent, the participants are block randomized to either the intervention or control group. Medication prescription for comorbid patients is challenging and may be attributed to marked inter-individual variations in general health, organ function, pharmacokinetic and pharmacodynamic properties, biological age and physical performance. The intervention group receive a medication review. It is hypothesized that the intervention is feasible and more patients in the intervention group will complete ≥1 deprescribing and/or ≥1 medication optimization 30 days after the beginning of the intervention than the patients in the control group. Secondary it is hypothesized the patients in the intervention group: A. Complete more deprescribing compared to the control group (30 days after intervention) B. Complete more medication optimization compared to the control group (30 days after intervention) C. Have a higher knowledge about own medication (14 days after intervention) D. Have a higher level of satisfaction with medication information (14 days after intervention)


Recruitment information / eligibility

Status Completed
Enrollment 72
Est. completion date March 5, 2021
Est. primary completion date December 30, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Consultation at Integrated Outpatient Department subacute track - Multi morbidity/Comorbidity - Drug Prescribing - Mentally fresh - Understand and speak Danish Exclusion Criteria: - Unable to cooperate cognitively - Language problems - Admission

Study Design


Intervention

Other:
Interdisciplinary Deprescribing and Medication Optimization Intervention
as current

Locations

Country Name City State
Denmark Capital Regional Hospital, Amager, Integrated Outpatient Department Copenhagen

Sponsors (2)

Lead Sponsor Collaborator
Region Hovedstadens Apotek Copenhagen University Hospital, Hvidovre

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility of a deprescribing and medication optimization: Number of patients who complete =1 deprescribing and/or =1 medication optimization 30 days after enrolment in each group. Number og patients who complete =1 deprescribing and/or =1 medication optimization 30 days after enrolment in the study. Baseline to 30 days after enrolment
Secondary Difference in patients between the two groups who completed =1 deprescribing and/or dose reduction 30 days after enrolment. Difference as %. Number of patients in the intervention group who complete =1 deprescribing and/or dose reduction than control group 30 days after enrolment in each group. Difference expressed as a percentage. Baseline to 30 days after enrolment
Secondary Difference in patients between the two groups who completed =1 medication optimization 30 days after enrolment in each group. Difference as % Number of patients in the intervention group who complete =1 medication optimization more than control group 30 days after enrolment in each group. Difference expressed as a percentage. Baseline to 30 days after enrolment
Secondary Difference in Knowledge between the two groups who gains more knowledge about their medication measured by =1 point on Likert scale (1-5 p). Number of patients in the intervention group who gains more knowledge about their medication measured by =1 point more than patients in the control group measured in difference in points on Likert scale (1-5 points). Where 5 points indicates high knowledge and 1 point is no knowledge. Difference expressed as a percentage Baseline to 14 days after enrolment
Secondary Difference in patients who are satisfied with medication information measured by =1 point on Likert scale (1-5 p). Number of patients in the intervention group who are more satisfied with medication information given by the Interdisciplinary team measured by =1 point than patients in control group measured in difference in points on Likert scale (1-5p). Where 5 points indicates high knowledge and 1 point is no knowledge. Difference expressed as a percentage Baseline to 14 days after enrolment
See also
  Status Clinical Trial Phase
Completed NCT02122198 - Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women N/A
Recruiting NCT04356924 - Psychological Treatment to Support the Consequences of Cognitive Impairment N/A
Suspended NCT05542238 - The Effect of Acute Exercise on Cardiac Autonomic, Cerebrovascular, and Cognitive Function in Spinal Cord Injury N/A
Terminated NCT04493957 - Evaluation of an Educational Program in the Prevention of the Driving Risks in Patients With Neurocognitive Disorders : ACCOMPAGNE N/A
Recruiting NCT04792983 - Cognition and the Immunology of Postoperative Outcomes
Completed NCT06029920 - Influence of Overground Walking on Biomarkers, Cognitive Function, and Quality of Life in Elderly With Mild Cognitive Impairment N/A
Not yet recruiting NCT05068323 - Impact of Interictal Epileptiform Activity on Some Cognitive Domains in Newly Diagnosed Epileptic Patients N/A
Completed NCT04426838 - Cognitive Behavioral Therapy for Insomnia for the Dementia Caregiving Dyad N/A
Completed NCT04713384 - Remote Bimanual Virtual Rehabilitation Post CVD N/A
Recruiting NCT06284213 - Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia Consortium
Recruiting NCT06053775 - Non-Invasive Brain Stimulation and Cognitive Training for Depressive Symptomatology Related to Breast Cancer (ONCODEP) N/A
Completed NCT03698695 - A Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil in Healthy Male Volunteers Phase 1
Not yet recruiting NCT05552729 - Effects of Different Doses of Vitamin D on Cancer-related Cognitive Impairment in Patients With Gastrointestinal Tumors Phase 1/Phase 2
Recruiting NCT03268109 - COGnitive ImpairmenT in Older HIV-infected Patients ≥ 65 Years Old
Completed NCT03301402 - Air Purifier to Improve Endothelial Function and Carotid Intima Thickness N/A
Completed NCT03187353 - IMProving Executive Function Study Phase 4
Completed NCT05395559 - Prevalence and Recognition of Cognitive Impairment in Hospitalized Patients: a Flash Mob Study
Recruiting NCT04907565 - Impact of Obesity on Post-operative Cognitive Dysfunction: Role of Adipose Tissue
Recruiting NCT05030285 - Telehealth Psychotherapy for Anxiety in Persons With Cognitive Impairment N/A
Recruiting NCT04897334 - Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke N/A